Date(s) - 05/16/2017
3:30 pm - 4:30 pm


Seattle WA

Randal Ketchem speaks on “Computational design and high throughput characterization to predict and repair molecular attributes”.


Antibodies undergo somatic hypermutation to obtain their high levels of both antigen specificity and affinity. Hypermutation also leads to molecular issues as therapeutic candidates. Early molecular analysis enables an integrated approach to therapeutic design encompassing in silico tools, high throughput screening, and development of predictive tools coupled with large scale data capture. Pushing molecular design earlier in the therapeutic pathway increases the success and lowers the cost of therapeutics.


Randal Ketchem received his Ph.D. in Molecular Biophysics from Florida State University, focusing on experimental protein structure determination, and continuing his training in structural biology in a postdoctoral fellowship at The Scripps Research Institute. Ketchem then joined Immunex in 1997 to apply his expertise in protein structure modeling and analysis to efforts in the development of biologic-based therapeutics. During his years of experience at Immunex, Amgen, and Just Biotherapeutics, he has led efforts to engineer protein therapeutics, applied novel therapeutic modalities and
computational methods for therapeutic design, and developed computational and experimental approaches to understanding and controlling biophysical properties of biological macromolecules. Ketchem has made contributions in antibody design, epitope mapping, molecular assessment, stability engineering, construct design, protein structure analysis, and protein engineering. At Just Biotherapeutics, Ketchem leads the molecular design team, integrating molecular design strategies into the entire therapeutic pipeline.